首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備 DDS

市場調查報告書

商品編碼

1560787

全球鼻內給藥市場 - 2024 - 2031

Global Intranasal Drug Delivery Market - 2024 - 2031

出版日期: 2024年09月23日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

2023年，全球鼻內給藥市場達112億美元，預計到2031年將達到207億美元，2024-2031年預測期間複合年成長率為8.0%。

鼻內給藥是一種經由鼻腔給藥的方法。此途徑利用鼻黏膜豐富的血管，使藥物繞過胃腸道和肝臟的首過代謝，直接吸收到血液中。

它為輸送各種藥物提供了一種非侵入性且方便的替代方案，包括全身藥物、疫苗以及針對鼻塞和過敏等局部病症的治療。快速吸收和起效使得鼻內給藥特別適用於需要快速緩解的病症，例如偏頭痛和疼痛。

市場動態：

驅動程式和限制

對非侵入性給藥方法的偏好日益增加

全球鼻內給藥市場受到對非侵入性方法日益成長的偏好的推動，這些方法提供快速起效和便利性。這種方法對於需要快速吸收的藥物特別有益，例如在緊急情況下或治療中樞神經系統疾病。鼻內給藥的便利性和患者依從性的提高也促進了其採用，特別是在口服或注射形式有困難的人群中，例如兒科和老年患者。

例如，2024 年 7 月，德州大學醫學分部的研究人員最近發現，在對抗阿茲海默症和失智症等神經退化性疾病方面取得了重大進展。這項發表在《科學轉化醫學》雜誌上的研究介紹了一種創新的鼻噴霧療法，該療法在清除有害tau 蛋白積聚和改善患有神經退化性疾病的老年小鼠模型的認知功能方面顯示出良好的效果。

吸收有限

由於局部刺激和鼻黏膜吸收有限，全球鼻內給藥市場面臨挑戰。由於鼻腔解剖結構和黏液纖毛清除率的原因，某些藥物可能會引起不適和吸收不一致。這些挑戰限制了需要精確劑量和一致吸收的藥物鼻內給藥的有效性和接受度。

細分市場分析

全球鼻內給藥市場根據類型、容器類型、應用、配銷通路和地區進行細分。

此類型細分市場的鼻噴霧劑約佔鼻內給藥市場佔有率的43.3%

鼻噴劑型段約佔43.3%。鼻噴霧劑是鼻內給藥市場上施用各種藥物的流行方法。它們將細小的藥物霧直接輸送到鼻腔中，以便快速吸收到血液中。這對於偏頭痛、鼻塞和過敏性鼻炎等速效藥物以及鴉片類藥物過量等緊急情況特別有用。鼻噴劑非侵入性且易於使用，使其成為注射或口服藥物的首選替代品。

例如，2023年10月，新一代鼻噴劑Otrivin Nasal Mist上市，為因感冒、過敏性鼻炎、鼻竇炎而鼻塞的人帶來更大的舒適感和易用性。這項創新技術由消費者健康公司 Haleon 和 Aptar Pharma 共同開發，採用新的微滴技術，噴出飽滿而溫和的霧氣，均勻覆蓋發炎區域，不會滴落到鼻子和喉嚨後部。

市場地域佔有率

預計北美在整個預測期內將佔據總市場佔有率的 38.4% 左右

由於意識的提高和醫療保健設施的改善，預計北美在整個預測期內將佔據約 38.4% 的總市場佔有率。政府措施和有利的報銷政策也促進了這一成長。亞洲預計將經歷高速成長，其中中國和印度由於大量投資、人口成長和政府資助而佔據主導地位。

例如，2024 年 4 月，Amneal Pharmaceuticals 宣佈在 FDA 批准後推出其非處方鹽酸納洛酮 (Naloxone HCI) 鼻噴霧劑，USP，4 毫克。這種通用等效藥物在美國製造，用於治療海洛因、芬太尼和處方鴉片類藥物等鴉片類藥物的藥物過量。 FDA 已批准該藥物。

It offers a non-invasive and convenient alternative for delivering various medications, including systemic drugs, vaccines, and treatments for local conditions like nasal congestion and allergies. The rapid absorption and onset of action make intranasal drug delivery particularly useful for conditions that require quick relief, such as migraines and pain.

Market Dynamics: Drivers & Restraints

Increasing preference for non-invasive drug administration methods

The global intranasal drug delivery market is driven by the growing preference for non-invasive methods, offering quick onset of action and convenience. This method is particularly beneficial for drugs requiring rapid absorption, such as in emergency settings or treating central nervous system disorders. The convenience and improved patient compliance of intranasal delivery are also boosting its adoption, especially among populations with difficulty with oral or injectable forms, such as pediatric and geriatric patients.

For instance, in July 2024, researchers at the University of Texas Medical Branch recently discovered a significant advancement in the fight against neurodegenerative diseases such as Alzheimer's disease and dementia. The study, published in Science Translational Medicine, introduces an innovative nasal spray treatment that has shown promising results in clearing harmful tau protein build-up and improving cognitive functions in aged mice models with neurodegenerative diseases.

Limited absorption

The global intranasal drug delivery market faces challenges due to local irritation and limited absorption through the nasal mucosa. Certain drugs can cause discomfort and inconsistent absorption due to nasal anatomy and mucociliary clearance rates. These challenges limit the effectiveness and acceptance of intranasal drug delivery for medications requiring precise dosing and consistent absorption.

Market Segment Analysis

The global intranasal drug delivery market is segmented based on type, container type, application, distribution channel, and region.

The nasal spray from the type segment accounted for approximately 43.3% of the intranasal drug delivery market share

The nasal spray from the type segment accounted for approximately 43.3%. Nasal sprays are a popular method for administering various medications in the intranasal drug delivery market. They deliver a fine mist of medication directly into the nasal cavity, allowing rapid absorption into the bloodstream. This is particularly useful for quick-onset drugs like migraines, nasal congestion, and allergic rhinitis, as well as emergencies like opioid overdose. Nasal sprays are non-invasive and easy to use, making them a preferred alternative to injections or oral medications.

For instance, in October 2023, Otrivin Nasal Mist, a new generation of nasal spray, was launched to bring greater comfort and ease of use to people suffering from nasal congestion due to colds, allergic rhinitis, and sinusitis. The innovation, developed by consumer health company Haleon and Aptar Pharma, uses new microdroplet technology to dispense a full but gentle mist that evenly covers inflamed areas, with no dripping at the back of the nose and throat.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increased awareness and improved healthcare facilities. Government initiatives and favorable reimbursement policies are also contributing to this growth. Asia is expected to experience high growth, with China and India dominating due to large investments, a rising population, and government funding.

For instance, in April 2024, Amneal Pharmaceuticals announced the availability of its Over-the-Counter Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following FDA approval. This generic equivalent is manufactured in the U.S. and is used to treat drug overdose from opioids like heroin, fentanyl, and prescription opioid medications. The FDA has approved the medication.

Market Segmentation

By Type

Nasal Spray

Nasal Drops

Nasal Gel

Nasal Powder

By Container Type

Pressurized Container

Non-pressurized Container

By Application

Allergic and Non-allergic Rhinitis

Nasal Congestion

Sinusitis

Asthma

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include AstraZeneca, Baxter International, Inc., Becton, Dickinson, and Company, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer Inc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc, Aegis Therapeutics LLC among others.

Key Developments

In November 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, just announced an expansion of its nasal drug delivery capabilities by adding a family of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal drug delivery is a good alternative to conventional delivery routes for both local and systemic drug delivery due to its simplicity, safety, and faster onset of action.

Why Purchase the Report?

To visualize the global intranasal drug delivery market segmentation based on type, container type, application, distribution channel, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the intranasal drug delivery market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global intranasal drug delivery market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Container Type
3.3. Snippet by Application
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing preference for non-invasive drug administration methods
  - 4.1.1.2. Rise in the prevalence of chronic diseases
- 4.1.2. Restraints
  - 4.1.2.1. Limited absorption
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 6.1.2. Market Attractiveness Index, By Type
6.2. Nasal Spray*
- 6.2.1. Introduction
6.3. Nasal Drops
6.4. Nasal Gel
6.5. Nasal Powder

7. By Container Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
7.2. Market Attractiveness Index, By Container Type
7.3. Pressurized Container*
- 7.3.1. Introduction
- 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Non-pressurized Container

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Allergic and Non-allergic Rhinitis*
- 8.2.1. Introduction
8.3. Nasal Congestion
8.4. Sinusitis
8.5. Asthma
8.6. Others

9. By Distribution Channel

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. The U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. UK
  - 10.3.7.3. France
  - 10.3.7.4. Italy
  - 10.3.7.5. Spain
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. AstraZeneca*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Baxter International, Inc
12.3. Becton, Dickinson, and Company
12.4. GlaxoSmithKline PLC
12.5. Johnson & Johnson
12.6. Novartis AG
12.7. Pfizer Inc
12.8. Valeant Pharmaceuticals International, Inc
12.9. Merck & Co., Inc
12.10. Aegis Therapeutics LLC (*LIST NOT EXHAUSTIVE)